AI assistant
NovoCure Ltd — Director's Dealing 2024
Jan 12, 2024
31949_dirs_2024-01-12_2fd114cd-4b8b-47b4-8277-2d026ba21afa.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2024-01-04
Reporting Person: Leonard Frank X (N/A)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Ordinary Shares | 45268.00 | Direct |
| Restricted Share Units | 5791.00 | Direct |
| Restricted Share Units | 2903.00 | Direct |
| Restricted Share Units | 2277.00 | Direct |
| Restricted Share Units | 6207.00 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Options (Right to buy) | $153.09 | 2031-03-01 | Ordinary Shares (16003.00) | Direct | |
| Stock Options (Right to buy) | $84.68 | 2030-08-31 | Ordinary Shares (11336.00) | Direct | |
| Stock Options (Right to buy) | $83.30 | 2029-07-30 | Ordinary Shares (7809.00) | Direct | |
| Stock Options (Right to buy) | $80.59 | 2032-02-29 | Ordinary Shares (4933.00) | Direct | |
| Stock Options (Right to buy) | $80.59 | 2032-02-29 | Ordinary Shares (30422.00) | Direct | |
| Stock Options (Right to buy) | $76.97 | 2033-02-27 | Ordinary Shares (30971.00) | Direct | |
| Stock Options (Right to buy) | $73.20 | 2032-10-31 | Ordinary Shares (11609.00) | Direct | |
| Stock Options (Right to buy) | $69.37 | 2030-03-02 | Ordinary Shares (1441.00) | Direct | |
| Stock Options (Right to buy) | $69.37 | 2030-03-02 | Ordinary Shares (8981.00) | Direct | |
| Stock Options (Right to buy) | $47.04 | 2029-03-21 | Ordinary Shares (14595.00) | Direct | |
| Stock Options (Right to buy) | $34.00 | 2028-07-30 | Ordinary Shares (16148.00) | Direct | |
| Stock Options (Right to buy) | $21.15 | 2028-02-26 | Ordinary Shares (10479.00) | Direct |
Footnotes
F1: Represents restricted share units that are scheduled to vest in equal installments on March 1, 2024 and 2025, subject to the reporting person's continued employment through such dates.
F10: Options to buy 30,971 ordinary shares will vest in equal installments on each of February 28, 2024, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates.
F11: Options to buy 11,609 ordinary shares, 2,903 shares of which are currently exercisable and the remainder will vest in equal installments on each of November 1, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates.
F12: Options to buy 10,422 ordinary shares, 7,817 shares of which are currently exercisable and the remainder will vest on March 2, 2024, subject to the reporting person's continued employment through such date.
F2: Represents restricted share units that are scheduled to vest on March 2, 2024, subject to the reporting person's continued employment through such date.
F3: Represents restricted share units that are scheduled to vest in equal installments on November 1, 2024 and 2025, subject to the reporting person's continued employment through such dates.
F4: Represents restricted share units that are scheduled to vest in equal installments on February 28, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates.
F5: Options to buy 16,003 ordinary shares, 8,002 shares of which are currently exercisable and the remainder will vest in equal installments on each of March 2, 2024 and 2025, subject to the reporting person's continued employment through such dates.
F6: Options to buy 11,336 ordinary shares, 8,502 shares of which are currently exercisable and the remainder will vest on September 1, 2024, subject to the reporting person's continued employment through such date.
F7: Currently exercisable.
F8: Options to buy 4,933 ordinary shares, 2,467 shares of which are currently exercisable and the remainder will vest on March 1, 2024, subject to the reporting person's continued employment through such date.
F9: Options to buy 30,422 ordinary shares, 7,606 shares of which are currently exercisable and the remainder will vest in equal installments on each of March 1, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates.